Akari Therapeutics PLC (AKTX)

Currency in USD
0.9769
+0.0069(+0.71%)
Real-time Data·
AKTX Scorecard
Full Analysis
Suffers from weak gross profit margins
AKTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.97011.0000
52 wk Range
0.85004.2185
Key Statistics
Prev. Close
0.985
Open
1
Day's Range
0.9701-1
52 wk Range
0.85-4.2185
Volume
7.19K
Average Volume (3m)
22.53K
1-Year Change
-73.31%
Book Value / Share
0.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AKTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.0000
Upside
+514.19%
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Akari Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Employees
9

Compare AKTX to Peers and Sector

Metrics to compare
AKTX
Peers
Sector
Relationship
P/E Ratio
−1.8x−3.9x−0.5x
PEG Ratio
−0.030.000.00
Price/Book
1.5x2.5x2.6x
Price / LTM Sales
-153.9x3.3x
Upside (Analyst Target)
-132.5%43.5%
Fair Value Upside
Unlock2.2%6.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.0000
(+514.19% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.14 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AKTX Income Statement

People Also Watch

3.4500
SNGX
+7.81%
5.43
REPL
-1.27%
2.1400
DARE
-5.31%
5.70
FDMT
-0.53%

FAQ

What Stock Exchange Does Akari Therapeutics Trade On?

Akari Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Akari Therapeutics?

The stock symbol for Akari Therapeutics is "AKTX."

What Is the Akari Therapeutics Market Cap?

As of today, Akari Therapeutics market cap is 32.13M.

What Is Akari Therapeutics's Earnings Per Share (TTM)?

The Akari Therapeutics EPS (TTM) is -1.05.

From a Technical Analysis Perspective, Is AKTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Akari Therapeutics Stock Split?

Akari Therapeutics has split 2 times.

How Many Employees Does Akari Therapeutics Have?

Akari Therapeutics has 9 employees.

What is the current trading status of Akari Therapeutics (AKTX)?

As of 07 Aug 2025, Akari Therapeutics (AKTX) is trading at a price of 0.98, with a previous close of 0.99. The stock has fluctuated within a day range of 0.97 to 1.00, while its 52-week range spans from 0.85 to 4.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.